US Patent 10,266,825: Scope, Claim Coverage, and US Patent Landscape for Chemically Synthesized Hybridizable Oligomers That Reduce Target mRNA
US Patent 10,266,825 claims a method of reducing a target messenger RNA (mRNA) in a cell by contacting the cell with a composition containing first and second chemically synthesized oligomeric compounds that are fully complementary to each other and hybridize to the target mRNA. The core commercial coverage is directed to complementary oligonucleotide pairs in which the “first” oligomer has a specific 2’-F/2’-O-CH3 motif pattern (F(SF)nSnn; n=2 to ~20; nn=0 or 1), and both oligomers are 17 to 23 nucleosides.
What patents protect US 10,266,825? How broad is claim coverage?
Hard core claim 1 coverage (method):
- A method of reducing target mRNA in a cell by contacting the cell with a composition comprising:
- First and second chemically synthesized oligomeric compounds
- First oligomer is fully complementary to and capable of hybridizing to:
- Second oligomer, and
- Target mRNA
- Each oligomer has 17 to 23 nucleosides (independent limitation)
- First oligomer includes at least one motif F(SF)nSnn:
- n = 2 to about 20
- nn = 0 or 1
- One nucleoside is 2’-F modified (F) and the other is 2’-O—CH3 modified (S) within the motif pattern
- Result: reducing target mRNA in the cell
Key breadth levers inside dependent claims:
- Claim 2 and 3 narrow which nucleoside class is F vs S (all F are either all 2’-O—CH3 or all 2’-F in specified versions).
- Claims 4–7 add end-group / backbone constraints:
- Optional 5’-phosphate on one or both oligomers
- Optional 3’-terminal OH on the first oligomer
- Claims 8–13 cover backbone linkage chemistry:
- Only phosphodiester
- Only phosphorothioate
- Mixed phosphodiester/phosphorothioate
- Broader list of other internucleoside or phosphorus linkage types (claim 13 is an extensive list)
- Claims 14–19 cover conjugates and terminal caps:
- “one conjugate group” generally
- conjugate attached at 3’ or 5’ end
- terminal caps at ends, including specific inverted deoxy abasic moieties
- claim 18/19 are structured to cover a sense strand with a capped end architecture
- Claims 20–21 provide explicit oligo types:
- complementary pair can be siRNA
- first oligomer can be an antisense oligonucleotide
Claim construction pressure points (where infringement risk concentrates)
- “First oligomeric compound” must include at least one motif F(SF)nSnn
This is the primary technical gate. If a competitor’s chemistry omits that motif pattern, claim 1 may be easier to design around.
- Both oligomers must be 17–23 nucleosides
Length outside that window is a clean non-infringement design option.
- Full complementarity between oligomers + hybridization to target mRNA
Some RNAi modalities use partial complementarity or different duplex architectures. Claim 1 requires a strong complementarity structure.
- Backbone and end-cap add-ons create layered coverage
Claims 8–13 and 16–19 expand coverage to common medicinal chemistry variations, which narrows design-around space if the competitor already uses those features.
Which embodiments are explicitly covered: siRNA, antisense, and defined end chemistries?
How does the patent cover siRNA oligonucleotide duplexes?
Claim 20 states that the first and second oligomers can be a complementary pair of siRNA oligonucleotides. This aligns the patent with:
- duplex siRNA formats
- chemically synthesized RNA-like strands
- motifs and backbone modifications used to stabilize duplexes and tune silencing potency
How does the patent cover antisense?
Claim 21 says the first oligomer can be an antisense oligonucleotide. That means the claims are not limited to duplex-only framing; it can capture:
- antisense strand chemistries that pair with a complementary partner oligomer capable of hybridizing to target mRNA
Which end modifications are covered?
The patent explicitly covers:
- 5’ phosphate (claims 4–6)
- 3’-terminal OH on the first oligomer (claim 7)
- a conjugate group (claims 14–15)
- terminal cap moieties at 3’ and/or 5’ (claims 16–19)
- includes inverted deoxy abasic moiety caps
These additions matter because many RNAi products use end modifications and protective caps to improve stability and reduce degradation.
What formulations are protected by US 10,266,825?
This patent is framed as a method of reducing target mRNA using a composition containing defined oligomer pairs. The claim text you provided does not enumerate dosage forms (lipid nanoparticles, conjugate carriers, polymers), but the claim architecture does cover:
- a composition comprising chemically synthesized oligomeric compounds
- with optional conjugates and terminal caps
- and defined backbone linkages (claim 13’s list)
In practice, the protected “formulation” scope likely tracks delivery-agnostic use of the oligomer pair, meaning infringement could occur regardless of delivery vehicle if the defined oligomers are delivered to cells and the method steps are satisfied.
How strong is the patent estate for this RNAi/mRNA reduction motif? Where is the novelty concentrated?
Based on the claims alone, the novelty appears concentrated in:
- the F/S motif pattern inside the first oligomer: F(SF)nSnn with defined 2’-F and 2’-O—CH3 roles
- the combined constraints of:
- length 17–23
- full complementarity to a second oligomer
- hybridization capability to target mRNA
- and the ability to reduce target mRNA
The breadth of claim 13 (many linkage chemistries) and the end-cap/conjugate options (claims 14–19) indicates the drafter anticipated common “workarounds” via backbone or termination modifications, then attempted to fold them back into coverage.
When does US 10,266,825 lose exclusivity? What is the patent expiration timeline?
You did not provide:
- the filing date, priority date, or
- any patent term adjustment (PTA) / term computations
- or maintenance status
Without those, a complete, accurate “expiration date” or exclusivity timeline cannot be produced from the claim text alone.
What generic entry risks exist for US 10,266,825?
This is a method-of-use and oligomer-structure-driven patent rather than a small-molecule composition-of-matter patent. For RNAi competitors, “generic” entry usually means:
- a new oligo sequence or chemistry with a different motif
- a different length window
- different backbone / end-caps
- or a different duplex architecture
Primary entry risk under this patent:
- a competitor using chemically synthesized complementary oligomers that are within 17–23 nucleosides
- and whose “first oligomer” includes the 2’-F/2’-O—CH3 motif pattern described
- and where the oligomers can hybridize to target mRNA and reduce mRNA in cells
Design-around levers:
- remove the required F(SF)nSnn motif from the first oligomer
- move oligomer length outside 17–23 nucleosides
- alter the duplex/partner relationship so the first is not fully complementary to the second as claimed
- change from hybridizing mechanisms that fail the “capable of hybridizing to target mRNA” limitation in the claimed sense (practical enforcement would hinge on claim interpretation and evidence)
How does US 10,266,825 compare with adjacent RNAi patent claim styles?
Comparison: motif-first vs modality-first claim drafting
- Many RNAi patents claim:
- siRNA length ranges,
- duplex end structure,
- “seed region” rules,
- chemical stabilization patterns (e.g., 2’-F, 2’-OMe globally),
- or general RNAi methods.
- US 10,266,825 is motif-first for the first oligomer (F(SF)nSnn) while also stacking many common chemistry variations (backbone types, caps, conjugates) through dependent claims.
The practical consequence: competitors may be able to avoid a “global modification” claim by changing overall substitution patterns, but they face a tighter constraint if the specific motif pattern must appear.
What patent litigation affects US 10,266,825?
No litigation docket information, enforcement actions, or court filings are included in the input. A complete and accurate litigation landscape cannot be produced from claim text alone.
What is the Orange Book status of US 10,266,825?
US patents are sometimes listed in regulatory patent registries tied to approved drug applications. However:
- the input does not specify any drug product, NDA/BLA/ANDA number, or Orange Book entry,
- and claim text alone does not identify the covered product(s).
A complete, accurate Orange Book mapping cannot be produced from the provided material.
Geographic coverage: does the claim strategy imply broader filings?
The claims provided are for US 10,266,825 only. Without the family details (priority and corresponding PCT/EP/CN/JP filings), a geographic landscape cannot be constructed accurately from claim text.
Key Takeaways
- US 10,266,825 covers a mRNA-reduction method using a chemically synthesized complementary oligomer pair where the first oligomer contains a specific 2’-F/2’-O-CH3 motif pattern (F(SF)nSnn) and both oligomers are 17 to 23 nucleosides.
- Dependent claims expand coverage to common medicinal chemistry variants:
- defined backbone internucleoside linking groups (including phosphodiester/phosphorothioate and a broader phosphorus linkage list),
- optional 5’ phosphate and 3’ OH,
- optional conjugates,
- optional terminal caps, including inverted deoxy abasic moieties,
- explicit framing as siRNA duplexes and as antisense embodiments.
- For freedom-to-operate, the highest-leverage design-around constraints are:
- eliminating the required F(SF)nSnn motif in the “first oligomer,” and/or
- moving oligomer lengths outside 17–23 nucleosides.
FAQs
-
If a competitor uses only 2’-OMe or only 2’-F substitutions, does US 10,266,825 still apply?
Claim 1 requires a motif with both roles of 2’-F and 2’-O—CH3 within F(SF)nSnn structure; pure mono-substitution patterns may avoid the motif limitation.
-
Can delivery vehicles (lipid nanoparticles, conjugate carriers) avoid infringement of this method claim?
The claim focuses on contacting cells with the defined oligomer composition and achieving mRNA reduction; delivery method does not negate the oligomer structure and method steps.
-
Does the patent require a particular target sequence or gene?
The claims define “target messenger RNA” generally and emphasize structural/chemical oligomer limitations rather than a named RNA sequence.
-
What backbone changes are explicitly captured by dependent claims?
Claims 8–13 cover phosphodiester and phosphorothioate variants and extend to a broad list of phosphorus linkage types in claim 13.
-
Is the invention limited to duplex RNAi only?
No. The claims explicitly include siRNA complementary pairs and also allow the first oligomer to be an antisense oligonucleotide, indicating broader RNA-silencing modality coverage than a duplex-only formulation.
References
- Provided: US Patent 10,266,825 claim text (user-provided).
